LYNX1 CAPITAL MANAGEMENT LP purchased 48.3% of their position (2.59M shares) of TSCAN THERAPEUTICS, INC. on the open market
Open‑market purchase worth $3.11M — a major conviction buy. The strongest form of insider conviction signal.
P · 2 purchases
Filed: 5/21/2025ACC: 0000902664-25-002511
10% Owner
Since May 2023
+2.59M
Net shares
Net buyer
$3.11M
Total acquired
2
Open market trades
2B · 0S
2
Total transactions
2.59M acquired
Non-Derivative Transactions2
Common stock, $0.0001 par value per share ("Common Stock")
Indirect
Shares
+1.39M
Price / share
$1.20
Trade value
$1.67M
% of position
25.9%
5/19/2025
5.36M→6.75M
Common Stock
Indirect
Shares
+1.20M
Price / share
$1.20
Trade value
$1.44M
% of position
17.8%
5/20/2025
6.75M→7.95M
Total
Net shares
+2.59M
Net value
$3.11M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common stock, $0.0001 par value per share ("Common Stock") Indirect | 5/19/2025 | P · Purchase | +1.39M | $1.20 | $1.67M | 25.9% | 5.36M | 6.75M |
| Common Stock Indirect | 5/20/2025 | P · Purchase | +1.20M | $1.20 | $1.44M | 17.8% | 6.75M | 7.95M |
| Total | +2.59M | $3.11M | ||||||
Derivative Transactions0
No derivative transactions reported